ALK and non-small cell lung carcinoma: However, EGFR/HER2 mutations and ALK, ROS, RET, and MET fusions defined NSCLC subsets with minimal benefit from ICB, despite high PDL1 expression indicating that PD-L1 expression and TMB seem to have an independent impact on sensitivity to IT.